Contact
Please use this form to send email to PR contact of this press release:
Momenta Pharmaceuticals Announces First Subject Dosed in Phase 1/2 Clinical Trial of M254, Hypersialylated Immunoglobulin G
TO:
Please use this form to send email to PR contact of this press release:
Momenta Pharmaceuticals Announces First Subject Dosed in Phase 1/2 Clinical Trial of M254, Hypersialylated Immunoglobulin G
TO: